Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the formation of hamartomas in multiple organs. Five to 15% of affected individuals display subependymal giant cell astrocytomas, which can lead to substantial neurological and postoperative morbidity due to the production of hydrocephalus, mass effect, and their typical location adjacent to the foramen of Monro. We sought to see whether therapy with oral rapamycin could affect growth or induce regression in astrocytomas associated with TSC.

[1]  Hongbing Zhang,et al.  Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. , 2004, Cancer research.

[2]  G. Schmid,et al.  Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. , 2005, Blood.

[3]  G. Watkins,et al.  Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. , 2005, European journal of cancer.

[4]  Hongbing Zhang,et al.  Perturbed IFN-γ-Jak-Signal Transducers and Activators of Transcription Signaling in Tuberous Sclerosis Mouse Models , 2004, Cancer Research.

[5]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Angelo Nicolin,et al.  mTOR: a protein kinase switching between life and death. , 2004, Pharmacological research.

[7]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[8]  Donghui Li,et al.  The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. , 2005, Biochemical and biophysical research communications.

[9]  M. Delgado,et al.  Early Diagnosis of Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis , 1998, Journal of child neurology.

[10]  A. Medhkour,et al.  Neonatal Subependymal Giant Cell Astrocytoma , 2002, Pediatric Neurosurgery.

[11]  D. Kwiatkowski.  Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis , 2003, Cancer biology & therapy.

[12]  J. Piatt,et al.  Spontaneous Involution of a Diencephalic Astrocytoma , 1998, Pediatric Neurosurgery.

[13]  B. Law,et al.  Rapamycin: an anti-cancer immunosuppressant? , 2005, Critical reviews in oncology/hematology.

[14]  E. Raymond,et al.  mTOR-targeted therapy of cancer with rapamycin derivatives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  D. Gutmann,et al.  Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. , 2005, Cancer research.

[16]  David M Sabatini,et al.  An expanding role for mTOR in cancer. , 2005, Trends in molecular medicine.

[17]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[18]  G. Gores,et al.  Hepatocellular carcinoma: molecular pathways and new therapeutic targets. , 2005, Seminars in liver disease.

[19]  C. Shields,et al.  Aggressive retinal astrocytomas in four patients with tuberous sclerosis complex. , 2004, Transactions of the American Ophthalmological Society.

[20]  A. Duhaime,et al.  Subependymal giant cell astrocytomas in children. , 1994, Pediatric neurosurgery.

[21]  Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779. , 2004, Drugs in R&D.

[22]  R. Yeung,et al.  Effects of Rapamycin in the Eker Rat Model of Tuberous Sclerosis Complex , 2005, Pediatric Research.

[23]  Mechanisms of action of rapamycin in gliomas. , 2005, Neuro-oncology.

[24]  I. Tannock,et al.  Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. , 2005, Cancer research.

[25]  R. Packer,et al.  Spontaneous Regression of Low-Grade Astrocytomas in Childhood , 2000, Pediatric Neurosurgery.

[26]  Shile Huang,et al.  Mechanisms of resistance to rapamycins. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[27]  P. Lindnér,et al.  Inhibition of mTOR suppresses experimental liver tumours. , 2005, Anticancer research.

[28]  Shiuan Chen,et al.  Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.

[29]  H. Takimoto,et al.  Glioblastoma following radiotherapy in a patient with tuberous sclerosis. , 1998, Neurologia medico-chirurgica.

[30]  S. Dashti,et al.  Pineal region giant cell astrocytoma associated with tuberous sclerosis: case report. , 2005, Journal of neurosurgery.

[31]  G. Thomas,et al.  The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb. , 2004, Novartis Foundation symposium.

[32]  A. Taratuto,et al.  Subependymal giant cell astrocytoma in children with tuberous sclerosis , 2003, Child's Nervous System.